InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ...

The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

Study finds cardiovascular events in pregnancy significantly increase risks for preterm birth and SGA infants in autoimmune ...

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

The risk of developing RDS was significantly increased among newborns born to mothers with confirmed COVID-19 infection during pregnancy.

The following is a summary of “Prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome,” published in the January ...

The Extracorporeal Life Support Organization has documented the application of venovenous extracorporeal membrane oxygenation ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

导读肺挫伤是指胸部创伤后对肺实质造成的直接或间接的损伤，肺挫伤后血液和其他体液在肺组织内积聚，过多的液体使通气/血流比失衡，从而导致缺氧。肺挫伤是引起急性肺损伤(acute lung injury, ALI)、急性呼吸窘迫综合征(acute ...